Seed Round

A massive USD 300M investment in a Quebec copper foil plant is set to eliminate a critical EV battery vulnerability for North America. Here's why.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

A key accelerator selection puts South Korean startup ALL CONEC and its AI-driven dental platform in the spotlight, backed by Oracle's cloud power.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.